Young Kids To Get Covid Vaccines Soon – What’s Next?

Young Kids To Get Covid Vaccines Soon – What’s Next?
SHARE

The novel coronavirus is still among us, and experts are making efforts with vaccines and treatments in r order to try and stop the pandemic. This coronavirus pandemic managed to change our lives, and this is probably for good. Check out the latest reports about the novel virus and the efforts to stop the pandemic. 

Kids and vaccines 

CNN just reported that about 28 million children ages 5 to 11 in the United States might soon be eligible for the Covid-19 vaccine. There are various plans in this direction. 

The US FDA’s independent vaccine advisory board will meet Tuesday to discuss whether Pfizer and BioNTech’s Covid-19 vaccine should be authorized for younger kids.

If the vaccine is authorized, this means that it would become the first vaccine available for younger children. Pfizer’s vaccine is already authorized for children 12 to 15 and is approved for people age 16 and older.

Source: pixabay.com

“If the FDA committee votes in its favor, the FDA will then make the final decision about whether to authorize it.
Then, the US Centers for Disease Control and Prevention independent advisory committee meets November 2 and 3, and will vote on whether to recommend it. Finally, CDC Director Dr. Rochelle Walensky will decide whether to accept or modify the committee’s recommendation,” CNN notes. 
In other words, this means that children could start getting Covid-19 shots immediately.

In an assessment that was posted late Friday night, the FDA also made sure to explain that the benefits of Pfizer/BioNTech’s Covid-19 vaccine outweigh the risks to children ages 5 to 11 under current pandemic conditions.

CNN noted the following critical issue:

“The FDA said the vaccine carries a theoretical risk of myocarditis or pericarditis that could require treatment and even hospitalization. But the risk of Covid-19 is higher if enough virus is circulating.”

Experts also addressed the situation,

“It’s a really high level of efficacy,” said Dr. Ashish Jha, the dean of the Brown University School of Public Health. He continued and said the following: 

“This is the kind of stuff we saw early days of Pfizer, before the Delta variant and other variants of concern came into effect, so I thought that was pretty compelling.”

Stay tuned for more news, and make sure to stay safe as well. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.